CG Oncology Inc. (CGON): Cretostimogene Could Become an Effective and Low-Side-Effect Alternative for Bladder Cancer Treatment!

CG Oncology Inc. (CGON) specializes in the development of novel cancer therapies, with a particular focus on bladder cancer. The company's main product is Cretostimogene grenadenorepvec (often simply referred to as "Cretostimogene"). This is an oncolytic immunotherapy that specifically targets cancer cells while simultaneously strengthening the immune system to combat cancer. In clinical studies, Cretostimogene has shown clinical benefit in patients with non-muscle invasive bladder cancer (NMIBC) who do not respond to Bacillus Calmette-Guérin...